脂质积累产物和心脏代谢指数作为肉症的指标:NHANES 2011-2018年的横截面研究
Xuyan Hu1, Yisong Yang1,2, Ke Gao1,3
1Department of Spine Surgery, Anhui No. 2 Provincial People's Hospital, No.1868 Dangshan Road, Yaohai District, Hefei, 230000, Anhui, China.
Scientific reports
|July 2, 2025
概括
脂质积累产物 (LAP) 和心脏代谢指数 (CMI) 与美国成年人的肉症风险有关. 较高的LAP和CMI水平显著增加了患上肉症的可能性.
科学领域:
- 代谢健康 代谢健康
- 老年学是一门学科.
- 流行病学 流行病学
背景情况:
- 脂质积累产物 (LAP) 和心脏代谢指数 (CMI) 是新出现的代谢功能障碍的标志物.
- 之前的研究表明LAP,CMI和肉眼之间存在潜在联系,但它们的直接关联需要进一步调查.
研究的目的:
- 调查脂质积累产品 (LAP) 和心脏代谢指数 (CMI) 与美国20-59岁成年人肉症之间的关联.
- 探索非线性关系,并确定LAP和CMI与sarcopenia相关的潜在切断点.
- 根据LAP和CMI开发和验证基于肉类风险的预测模型.
主要方法:
- 从NHANES 2011-2018数据对4,172名成年人的横截面分析.
- 作为主要暴露物,日志转换的LAP和CMI;由尾骨肌肉质量/BMI比率定义的肉症.
- 多变量后勤回归,受限制的立方线,值分析,LASSO回归和预测建模的名ogram开发.
主要成果:
- 经日志转换的LAP (Ln LAP) 和CMI (Ln CMI) 显著与增加肉症的几率有关.
- 值分析显示了Ln LAP (4.64) 和Ln CMI (-0.14) 的拐点.
- Ln LAP (OR=8.78) 和 Ln CMI (OR=4.44) 的高四分位数显示了显著更高的肉症几率;模型显示了强大的预测准确性 (AUCs ~0.77-0.78).
结论:
- 脂质积累产物 (LAP) 和心脏代谢指数 (CMI) 正面和非线性地与美国成年人的肉类有关.
- 这些代谢标志物可以帮助识别患有肉类的风险较高的个体.
- 这些发现支持在临床环境中使用LAP和CMI来评估和管理肉症风险.
相关概念视频
Coronary Artery Disease I: Introduction
67
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
67
Obesity
624
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
624
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
222
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
222
Overview of Lipid Metabolism
2.5K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.5K
Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
Atherosclerosis I: Introduction
93
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
93


